Brind.
  1. Enanta Pharmaceuticals partnered with AbbVie on VIEKIRA PAK, and GelTex Pharmaceuticals, Inc. was acquired by Genzyme Corporation.

Enanta Pharmaceuticals received royalties from HCV products to fund its operations.

4 reports, 1 independent Updated Aug 21
Gone quiet
Reports
4
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Enanta Pharmaceuticals received royalties from HCV products to fund its operations.

Who's involved

What this event is mainly about
AbbVieEnanta Pharmaceuticals (United States)

How it developed

Newest first. Tap a step to see who reported it.
  1. Enanta's operations are being funded by royalties from HCV products.1 source
  2. Enanta is targeting KIT inhibition for inflammatory diseases, alongside receiving royalties from AbbVie.1 source

Keep exploring

Part of

Enanta Pharmaceuticals partnered with AbbVie on VIEKIRA PAK, and GelTex Pharmaceuticals, Inc. was acquired by Genzyme Corporation. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Business WireEnanta Pharmaceuticals to Participate in September Investor Conferences WATERTOWN, Mass., August 21, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology
  • Business WireEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 On Track to Report Topline Data for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infecte
  • Business WireEnanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. "HCW@Home" Series WATERTOWN, Mass., August 05, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage b
  • Business WireEnanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series WATERTOWN, Mass., July 15, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology